108 related articles for article (PubMed ID: 19038763)
1. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Edwards BJ; Gounder M; McKoy JM; Boyd I; Farrugia M; Migliorati C; Marx R; Ruggiero S; Dimopoulos M; Raisch DW; Singhal S; Carson K; Obadina E; Trifilio S; West D; Mehta J; Bennett CL
Lancet Oncol; 2008 Dec; 9(12):1166-72. PubMed ID: 19038763
[TBL] [Abstract][Full Text] [Related]
2. Pulp and periapical disease as a risk factor for osteonecrosis of the jaw: a national cohort-based study in Korea.
Baek HJ; Lee H; Lee JR; Park JH; Kim KS; Kwoen MJ; Lee TY; Kim JW; Lee HJ
J Periodontal Implant Sci; 2024 Apr; 54(2):65-74. PubMed ID: 37524381
[TBL] [Abstract][Full Text] [Related]
3. Closure of an open wound associated with bisphosphonate-related osteonecrosis of the jaw in a breast cancer patient.
Soolari N; Soolari A
Open Dent J; 2011; 5():163-7. PubMed ID: 22135700
[TBL] [Abstract][Full Text] [Related]
4. Improving Bisphosphonate Infusion Monitoring at Haematology Medical Day Unit.
Ong MWS; Jones L
BMJ Qual Improv Rep; 2017; 6(1):. PubMed ID: 28469896
[TBL] [Abstract][Full Text] [Related]
5. [Adverse drug reactions in the oral cavity].
Böttiger Y; Ekenstråle E
Lakartidningen; 2024 Mar; 121():. PubMed ID: 38470273
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis caused by Bisphosphonates: a clinical case.
Spinelli D; DE Vico G; Bonino M; Barlattani A; Bollero P; Barlattani A
Oral Implantol (Rome); 2009 Oct; 2(4):26-34. PubMed ID: 23285372
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Khan AA; Morrison A; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Al Dabagh R; Davison KS; Kendler DL; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Bone Miner Res; 2015 Jan; 30(1):3-23. PubMed ID: 25414052
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Kharazmi M; Persson U; Warfvinge G
J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Lo JC; O'Ryan FS; Gordon NP; Yang J; Hui RL; Martin D; Hutchinson M; Lathon PV; Sanchez G; Silver P; Chandra M; McCloskey CA; Staffa JA; Willy M; Selby JV; Go AS;
J Oral Maxillofac Surg; 2010 Feb; 68(2):243-53. PubMed ID: 19772941
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Assessment of Medication-Related Osteonecrosis of the Jaw Using [18F]fluoride Positron Emission Tomography (PET)/CT and [18F]fluorodeoxyglucose PET/MRI in Correlation with Histomorphometry and Micro-CT-A Prospective Comparative Study.
Reinert CP; Pfannenberg C; Gückel B; Dittmann H; la Fougère C; Nikolaou K; Reinert S; Schönhof R; Hoefert S
Diagnostics (Basel); 2024 Feb; 14(4):. PubMed ID: 38396467
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer.
Senín LD; Pancorbo DM; Garcés MYR; Santos-Rubio MD; Calero JB
Curr Oncol; 2024 Jan; 31(1):250-259. PubMed ID: 38248101
[TBL] [Abstract][Full Text] [Related]
13. Addressing Osteonecrosis: A preventable catastrophe - A multi-center study.
Alam M; Khan ZM; Alam L; Faraid V; Khan A
Pak J Med Sci; 2023; 39(1):262-267. PubMed ID: 36694740
[TBL] [Abstract][Full Text] [Related]
14. A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling.
Kang HK; Park CY; Jung SY; Jo SB; Min BM
Tissue Eng Regen Med; 2022 Dec; 19(6):1359-1376. PubMed ID: 36207661
[TBL] [Abstract][Full Text] [Related]
15. Oral Abundance of Actinomyces spp. in Breast Cancer Patients.
Bilgilier C; Fuereder T; Kastner MT; Vass Z; Brandl I; Sahbegovic H; Singer CF; Steininger C
Oncology; 2022; 100(4):221-227. PubMed ID: 35051923
[TBL] [Abstract][Full Text] [Related]
16.
Reinert CP; Pfannenberg C; Gatidis S; la Fougère C; Nikolaou K; Hoefert S
Front Oncol; 2021; 11():700397. PubMed ID: 34277447
[TBL] [Abstract][Full Text] [Related]
17. Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare.
Zhou J; Sweiss K; Nutescu EA; Han J; Patel PR; Ko NY; Lee TA; Chiu BC; Calip GS
JCO Oncol Pract; 2021 Mar; 17(3):e294-e312. PubMed ID: 33449809
[TBL] [Abstract][Full Text] [Related]
18. Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by Suppressing the NF-κB and P38 MAPK Signaling Pathways.
Hu X; Yin Z; Chen X; Jiang G; Yang D; Cao Z; Li S; Liu Z; Peng D; Dou P
Front Pharmacol; 2020; 11():385. PubMed ID: 32317967
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan.
Hibi H
Nagoya J Med Sci; 2020 Feb; 82(1):1-3. PubMed ID: 32273626
[TBL] [Abstract][Full Text] [Related]
20. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.
Wan JT; Sheeley DM; Somerman MJ; Lee JS
Bone Res; 2020; 8():14. PubMed ID: 32195012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
